Database→Retatrutide

Tier 1–2Weight LossMetabolicDiabetesPREMIUM

Retatrutide

Retatrutide (LY3437943) · Triple GIP/GLP-1/Glucagon Receptor Agonist

Not FDA or EMA approved as of March 2026. Investigational pharmaceutical drug under active Phase 3 TRIUMPH program by Eli Lilly. Not available outside clinical trials. TRIUMPH-4 Phase 3 (December 2025) met all primary and key secondary endpoints.

For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use

Profile Overview

Retatrutide (LY3437943) is a purpose-engineered triple agonist targeting GLP-1, GIP, and glucagon receptors, developed by Eli Lilly. It is the most clinically advanced compound in this research series and has produced the highest weight loss ever documented in a pharmaceutical trial (28.7% at 68 weeks in Phase 3). The TRIUMPH Phase 3 program covers 8 indications in 5,800+ patients across 13 countries. First readout (TRIUMPH-4, December 2025) met all primary and key secondary endpoints.

🔒

Full Profile: Premium Members Only

The complete Retatrutide profile includes all use cases with full evidence reviews, mechanism of action deep dive, safety analysis, evidence table, dosing guidance, and stack compatibility data.

For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use